Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017132059) INACTIVATION OF VIRUSES BY DELIPIDATION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/132059 International Application No.: PCT/US2017/014267
Publication Date: 03.08.2017 International Filing Date: 20.01.2017
IPC:
C07K 14/08 (2006.01) ,C12N 7/06 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005
from viruses
08
RNA viruses
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04
Inactivation or attenuation; Producing viral sub-units
06
by chemical treatment
Applicants:
ELANCO US INC. [US/US]; 2500 Innovation Way Greenfield, Indiana 46140, US
Inventors:
DIAZ, Leyla; US
WU, Stephen; US
Agent:
PFLUGH, David, L.; US
MCGRAW, Elizabeth A.; US
Priority Data:
62/287,48827.01.2016US
Title (EN) INACTIVATION OF VIRUSES BY DELIPIDATION
(FR) INACTIVATION DE VIRUS PAR DÉLIPIDATION
Abstract:
(EN) The present invention relates to vaccines containing enveloped viruses whose envelopes have been depleted of lipids using methyl β-cyclodextrin (MBCD). Delipidation of enveloped viruses in a two-step process abolishes the infectivity of those viruses, which allows delipidated viruses to be used safely in vaccines. Use of MBCD to deplete lipids such as cholesterol, in contrast to other methods, results in viruses with less than 20% of the cholesterol of an untreated virus but such delipidated viruses retain at least 85% of the protein content of an untreated virus. Delipidation by MBCD also preserves the immunogenicity of the viral proteins. The present invention of using MBCD treatment in a two-step process to delipidate enveloped virus represents a new alternative for generation of inactivated viruses which are incorporated into effective vaccines.
(FR) La présente invention concerne des vaccins comprenant des virus enveloppés dont les lipides des enveloppes ont été épuisés à l'aide de méthyl-β-cyclodextrine (MBCD). La délipidation des virus enveloppés dans un procédé en deux étapes supprime l'infectivité de ces virus, ce qui permet aux virus délipidés d'être utilisés en toute sécurité dans des vaccins. L'utilisation de MBCD en vue d'épuiser des lipides tels que le cholestérol, contrairement à d'autres procédés, a pour conséquence des virus présentant moins de 20 % du cholestérol d'un virus non traité mais ces virus délipidés conservent au moins 85 % de la teneur en protéines d'un virus non traité. La délipidation par MBCD préserve également l'immunogénicité des protéines virales. La présente invention, consistant à utiliser un traitement par MBCD dans un procédé en deux étapes pour la délipidation du virus enveloppé, constitue une nouvelle alternative pour la génération de virus inactivés qui sont incorporés dans des vaccins efficaces.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU2017211040CA3008965KR1020180096775ID2018/09781CN108602860EP3408280
US20180360945IN201817028067BR112018014542EA201891371